Kyu Hyun Park
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Kyu Hyun Park has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Eungu Kang
Department of Pediatrics, Korea University Ansan Hospital, Korea University College of Medicine, Ansan, Korea
5 shared publications - Hyo-Kyoung Nam
Department of Pediatrics, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Korea
5 shared publications - Kee-Hyoung Lee
Department of Pediatrics, College of Medicine, Korea University, Seoul 02841, Republic of Korea
5 shared publications - Young-Jun Rhie
Department of Pediatrics, Korea University College of Medicine, Seoul, Korea
5 shared publications - Young June Choe
Department of Pediatrics, Korea University College of Medicine, Seoul, Republic of Korea
3 shared publications - Yu Jin Kim
Department of Pediatrics, Korea University College of Medicine, Seoul, Korea
3 shared publications
Latest Publications
- Open Access
- 31 October 2025
- Published by Korean Society of Pediatric Endocrinology in Annals of Pediatric Endocrinology & Metabolism
- Vol. 30 (5) , 268-274
The role of continuous glucose monitoring in improving glycemic control in adolescents with type 1 diabetes
Purpose: Continuous glucose monitoring (CGM) technology offers real-time glucose feedback and has shown potential to improve glycemic control. This retrospective study evaluated the effect of CGM on glycemic outcomes in Korean children and adolescents with type 1 diabetes mellitus (T1DM) in a real-world setting.Methods: We included 66 participants divided into a CGM group (n=22) and a self-monitoring blood glucose (SMBG) group (n=44). We compared changes in hemoglobin A1c (HbA1c) of the 2 groups over 1 year and observed changes in CGM activation time, mean glucose, glucose management indicator (GMI), coefficient of variation (CV), time in range (TIR), and hypoglycemia.Results: The CGM group had a mean age of 16.63 years and time from diagnosis to the initiation of study of 4.19 years, while those of the SMBG group were 17.85 years and 5.19 years, respectively. In the CGM group, mean HbA1c decreased from 8.68% at baseline to 7.92% at 12 months (P=0.011), whereas HbA1c increased from 8.46% to 8.93% in the SMBG group (P<0.001). The changes in HbA1c at 1 year between the CGM and SMBG groups were significantly different (-0.76%±1.39% vs. 0.47%±1.38%, P=0.001). CGM activation time decreased slightly (89.09% to 79.24%, P=0.093), and there were no significant changes in TIR, mean glucose, GMI, CV, or hypoglycemia over time.Conclusion: CGM use in Korean children and adolescents with T1DM significantly improves HbA1c levels over 12 months compared to SMBG. The implementation of CGM may provide valuable benefits in glycemic control and potentially reduce the risk of diabetes-related complications.
- 31 October 2025
- Published by Korean Society of Pediatric Endocrinology in Annals of Pediatric Endocrinology & Metabolism
- Vol. 30 (5) , 268-274
Open AccessThe role of continuous glucose monitoring in improving glycemic control in adolescents with type 1 diabetes
Purpose: Continuous glucose monitoring (CGM) technology offers real-time glucose feedback and has shown potential to improve glycemic control. This retrospective study evaluated the effect of CGM on glycemic outcomes in Korean children and adolescents with type 1 diabetes mellitus (T1DM) in a real-world setting.Methods: We included 66 participants divided into a CGM group (n=22) and a self-monitoring blood glucose (SMBG) group (n=44). We compared changes in hemoglobin A1c (HbA1c) of the 2 groups over 1 year and observed changes in CGM activation time, mean glucose, glucose management indicator (GMI), coefficient of variation (CV), time in range (TIR), and hypoglycemia.Results: The CGM group had a mean age of 16.63 years and time from diagnosis to the initiation of study of 4.19 years, while those of the SMBG group were 17.85 years and 5.19 years, respectively. In the CGM group, mean HbA1c decreased from 8.68% at baseline to 7.92% at 12 months (P=0.011), whereas HbA1c increased from 8.46% to 8.93% in the SMBG group (P<0.001). The changes in HbA1c at 1 year between the CGM and SMBG groups were significantly different (-0.76%±1.39% vs. 0.47%±1.38%, P=0.001). CGM activation time decreased slightly (89.09% to 79.24%, P=0.093), and there were no significant changes in TIR, mean glucose, GMI, CV, or hypoglycemia over time.Conclusion: CGM use in Korean children and adolescents with T1DM significantly improves HbA1c levels over 12 months compared to SMBG. The implementation of CGM may provide valuable benefits in glycemic control and potentially reduce the risk of diabetes-related complications.
- Open Access
- 30 June 2025
- Published by Korean Society of Pediatric Endocrinology in Annals of Pediatric Endocrinology & Metabolism
- Vol. 30 (3) , 127-134
Predicting variables associated with diagnostic reevaluation of transient congenital hypothyroidism
Purpose: Current guidelines recommend immediate treatment after diagnosis of congenital hypothyroidism and reassessment of the hypothalamic-pituitary-thyroid axis at 3 years of age. As the known incidence of transient congenital hypothyroidism (TCH) has increased, experts have suggested the possibility of early drug discontinuation. Distinguishing TCH from permanent congenital hypothyroidism (PCH) is important to avoid prolonged treatment. We aimed to investigate the factors associated with TCH and to identify markers that indicate patients suitable for early treatment discontinuation.Methods: Participants were 167 children with congenital hypothyroidism. Subjects attempting to discontinue levothyroxine before 2 years of age were defined as the "early-off group." Cox proportional hazards models were used to identify factors associated with TCH and to determine factors predicting early drug discontinuation.Results: Totals of 96 (57%) and 71 children (43%) were classified as having TCH and PCH, respectively. In the Cox multivariate analysis, gestational age (GA) and low levothyroxine dose at 24 months of age were statistically associated with TCH. Based on receiver operating characteristic (ROC) curve analysis, an optimal cutoff dose for levothyroxine of 3.03 µg/kg/day at 18 months of age can predict early treatment discontinuation (P<0.001; sensitivity, 75.0%; specificity, 72.9%; area under the curve, 0.778).Conclusion: Our study showed that lower GA and lower levothyroxine doses during treatment were highly suggestive of TCH. Those requiring lower levothyroxine levels at 18 months of age could be candidates to cease medication prior to 3 years of age.
- 30 June 2025
- Published by Korean Society of Pediatric Endocrinology in Annals of Pediatric Endocrinology & Metabolism
- Vol. 30 (3) , 127-134
Open AccessPredicting variables associated with diagnostic reevaluation of transient congenital hypothyroidism
Purpose: Current guidelines recommend immediate treatment after diagnosis of congenital hypothyroidism and reassessment of the hypothalamic-pituitary-thyroid axis at 3 years of age. As the known incidence of transient congenital hypothyroidism (TCH) has increased, experts have suggested the possibility of early drug discontinuation. Distinguishing TCH from permanent congenital hypothyroidism (PCH) is important to avoid prolonged treatment. We aimed to investigate the factors associated with TCH and to identify markers that indicate patients suitable for early treatment discontinuation.Methods: Participants were 167 children with congenital hypothyroidism. Subjects attempting to discontinue levothyroxine before 2 years of age were defined as the "early-off group." Cox proportional hazards models were used to identify factors associated with TCH and to determine factors predicting early drug discontinuation.Results: Totals of 96 (57%) and 71 children (43%) were classified as having TCH and PCH, respectively. In the Cox multivariate analysis, gestational age (GA) and low levothyroxine dose at 24 months of age were statistically associated with TCH. Based on receiver operating characteristic (ROC) curve analysis, an optimal cutoff dose for levothyroxine of 3.03 µg/kg/day at 18 months of age can predict early treatment discontinuation (P<0.001; sensitivity, 75.0%; specificity, 72.9%; area under the curve, 0.778).Conclusion: Our study showed that lower GA and lower levothyroxine doses during treatment were highly suggestive of TCH. Those requiring lower levothyroxine levels at 18 months of age could be candidates to cease medication prior to 3 years of age.
- Open Access
- 30 June 2024
- Published by Korean Society of Pediatric Endocrinology in Annals of Pediatric Endocrinology & Metabolism
- Vol. 29 (3) , 161-166
Long-term efficacy of a triptorelin 3-month depot in girls with central precocious puberty
Purpose: Three-month gonadotropin-releasing hormone agonists (GnRHas) are expected to achieve better compliance in patients with central precocious puberty (CPP) compared to the monthly formulation. However, 1-month depot remains the dominant choice for conventional treatment worldwide. Our study aimed to investigate the long-term efficacy of a 3-month GnRHa for CPP treatment.Methods: In this retrospective study, 69 Korean girls with CPP were prescribed either triptorelin pamoate (TP) 3-month depot (n=29) or triptorelin acetate (TA) 1-month depot (n=40) and were followed for 1 year after the end of treatment. Auxological, radiological, and biochemical data were collected every 6 months.Results: Baseline characteristics were similar between the 2 groups. In the TP 3-month depot group, 27 of 29 patients (93.1%) exhibited suppressed luteinizing hormone level (below 2.5 IU/L) after 6 months of treatment, and this suppression level was reserved until the final injection. The degree of bone age advancement in the TP 3-month depot group decreased from 1.8±0.4 years at the start of treatment to 0.6±0.5 years at 1-year posttreatment. The gain in predicted adult height (PAH) 1 year after the end of treatment was similar between the TP 3-month and TA 1-month depot groups (5.2±3.1 and 5.3±2.4 cm, respectively; p=0.875).Conclusion: A 3-month depot of triptorelin effectively inhibited gonadal and sex hormones, suppressed bone maturation, and increased PAH. For patient convenience, we suggest a 3-month GnRHa regimen as a promising CPP treatment option.
- 30 June 2024
- Published by Korean Society of Pediatric Endocrinology in Annals of Pediatric Endocrinology & Metabolism
- Vol. 29 (3) , 161-166
Open AccessLong-term efficacy of a triptorelin 3-month depot in girls with central precocious puberty
Purpose: Three-month gonadotropin-releasing hormone agonists (GnRHas) are expected to achieve better compliance in patients with central precocious puberty (CPP) compared to the monthly formulation. However, 1-month depot remains the dominant choice for conventional treatment worldwide. Our study aimed to investigate the long-term efficacy of a 3-month GnRHa for CPP treatment.Methods: In this retrospective study, 69 Korean girls with CPP were prescribed either triptorelin pamoate (TP) 3-month depot (n=29) or triptorelin acetate (TA) 1-month depot (n=40) and were followed for 1 year after the end of treatment. Auxological, radiological, and biochemical data were collected every 6 months.Results: Baseline characteristics were similar between the 2 groups. In the TP 3-month depot group, 27 of 29 patients (93.1%) exhibited suppressed luteinizing hormone level (below 2.5 IU/L) after 6 months of treatment, and this suppression level was reserved until the final injection. The degree of bone age advancement in the TP 3-month depot group decreased from 1.8±0.4 years at the start of treatment to 0.6±0.5 years at 1-year posttreatment. The gain in predicted adult height (PAH) 1 year after the end of treatment was similar between the TP 3-month and TA 1-month depot groups (5.2±3.1 and 5.3±2.4 cm, respectively; p=0.875).Conclusion: A 3-month depot of triptorelin effectively inhibited gonadal and sex hormones, suppressed bone maturation, and increased PAH. For patient convenience, we suggest a 3-month GnRHa regimen as a promising CPP treatment option.
- Open Access
- 30 April 2024
- Published by Korean Society of Pediatric Endocrinology in Annals of Pediatric Endocrinology & Metabolism
- Vol. 29 (2) , 90-94
Effectiveness of the triptorelin stimulation test compared with the classic gonadotropin-releasing hormone stimulation test in diagnosing central precocious puberty in girls
Purpose: The gonadotropin-releasing hormone (GnRH) stimulation test is the gold standard for diagnosing central precocious puberty (CPP). Gonadorelin (Relefact) is used for the test but is not always readily available; triptorelin is used as an alternative. The purpose of this study was to evaluate the diagnostic validity of the triptorelin test compared with the GnRH test in the diagnosis of CPP in girls.Methods: This retrospective study included 100 girls with premature thelarche (PT) who underwent a hypothalamic-pituitary-gonadal axis evaluation. In the overall group, 50 girls were tested with intravenous gonadorelin (Relefact) and 50 girls were tested with subcutaneous triptorelin acetate (Decapeptyl). Luteinizing hormone (LH) and follicle-stimulating hormone levels were measured at baseline and 30, 45, 60, and 90 minutes after gonadorelin injection or 30, 60, 90, and 120 minutes after triptorelin injection.Results: Clinical characteristics of age, height, weight, body mass index, and bone age were similar between the 2 groups. The highest LH level was reached 60 minutes after stimulation in both groups. Approximately 20% of the gonadorelin group and 24% of the triptorelin group were diagnosed with CPP (P=0.52). Among those diagnosed with CPP, the mean peak LH concentrations were 8.15 mIU/mL and 9.73 mIU/mL in the gonadorelin and triptorelin groups, respectively.Conclusion: The triptorelin test showed similar trends of LH elevation and diagnostic rate compared with the traditional GnRH test for diagnosing CPP. This suggests that the triptorelin test may be a valid alternative to the GnRH test for differentiating CPP from self-limiting PT. Our study also demonstrated that a triptorelin stimulation test for up to 120 minutes was sufficient to diagnose CPP.
- 30 April 2024
- Published by Korean Society of Pediatric Endocrinology in Annals of Pediatric Endocrinology & Metabolism
- Vol. 29 (2) , 90-94
Open AccessEffectiveness of the triptorelin stimulation test compared with the classic gonadotropin-releasing hormone stimulation test in diagnosing central precocious puberty in girls
Purpose: The gonadotropin-releasing hormone (GnRH) stimulation test is the gold standard for diagnosing central precocious puberty (CPP). Gonadorelin (Relefact) is used for the test but is not always readily available; triptorelin is used as an alternative. The purpose of this study was to evaluate the diagnostic validity of the triptorelin test compared with the GnRH test in the diagnosis of CPP in girls.Methods: This retrospective study included 100 girls with premature thelarche (PT) who underwent a hypothalamic-pituitary-gonadal axis evaluation. In the overall group, 50 girls were tested with intravenous gonadorelin (Relefact) and 50 girls were tested with subcutaneous triptorelin acetate (Decapeptyl). Luteinizing hormone (LH) and follicle-stimulating hormone levels were measured at baseline and 30, 45, 60, and 90 minutes after gonadorelin injection or 30, 60, 90, and 120 minutes after triptorelin injection.Results: Clinical characteristics of age, height, weight, body mass index, and bone age were similar between the 2 groups. The highest LH level was reached 60 minutes after stimulation in both groups. Approximately 20% of the gonadorelin group and 24% of the triptorelin group were diagnosed with CPP (P=0.52). Among those diagnosed with CPP, the mean peak LH concentrations were 8.15 mIU/mL and 9.73 mIU/mL in the gonadorelin and triptorelin groups, respectively.Conclusion: The triptorelin test showed similar trends of LH elevation and diagnostic rate compared with the traditional GnRH test for diagnosing CPP. This suggests that the triptorelin test may be a valid alternative to the GnRH test for differentiating CPP from self-limiting PT. Our study also demonstrated that a triptorelin stimulation test for up to 120 minutes was sufficient to diagnose CPP.
- Open Access
- 30 September 2023
- Published by Korean Society of Pediatric Endocrinology in Annals of Pediatric Endocrinology & Metabolism
- Vol. 28 (3) , 200-205
Brain magnetic resonance imaging (MRI) findings in central precocious puberty patients: is routine MRI necessary for newly diagnosed patients?
Purpose: The overall incidence of central precocious puberty (CPP) has increased in recent decades, and brain magnetic resonance imaging (MRI) evaluations are recommended in cases of suspected brain lesions. This study aimed to investigate the prevalence of MRI abnormalities and to evaluate the need for routine brain MRI in patients with newly diagnosed CPP.Methods: This retrospective study reviewed the data of patients newly diagnosed with CPP who underwent routine pituitary MRI at Korea University Anam Hospital from March 2020 to September 2021. A total of 199 girls and 24 boys was enrolled in this study. Positive MRI findings were categorized as abnormal pituitary, nonpituitary incidental, and pathological. In addition, we investigated the incidence of MRI abnormalities and evaluated their associations with clinical and biochemical factors.Results: Positive brain MRI findings were observed in 84 patients (37.7%). Pituitary abnormalities were found in 54 patients (24.2%), with Rathke cleft cysts being the most common (16.1%). Incidental nonpituitary findings were observed in 29 patients (13.0%), while a pathological brain lesion (diagnosed as hypothalamic hamartoma) was observed in only 1 female patient (0.4%). No significant differences in sex or age were found in incidence of pituitary abnormalities or nonpituitary incidental findings. Compared with headache controls, significant associations were observed between abnormal pituitary findings on MRI and CPP (unadjusted odds ratio, 3.979; 95% confidence interval, 1.726–9.173).Conclusion: True pathological findings were rare, even though the prevalence of abnormalities on pituitary MRI in patients with CPP was relatively high. Considering its cost-effectiveness, MRI screenings should be carefully considered in patients with CPP.
- 30 September 2023
- Published by Korean Society of Pediatric Endocrinology in Annals of Pediatric Endocrinology & Metabolism
- Vol. 28 (3) , 200-205
Open AccessBrain magnetic resonance imaging (MRI) findings in central precocious puberty patients: is routine MRI necessary for newly diagnosed patients?
Purpose: The overall incidence of central precocious puberty (CPP) has increased in recent decades, and brain magnetic resonance imaging (MRI) evaluations are recommended in cases of suspected brain lesions. This study aimed to investigate the prevalence of MRI abnormalities and to evaluate the need for routine brain MRI in patients with newly diagnosed CPP.Methods: This retrospective study reviewed the data of patients newly diagnosed with CPP who underwent routine pituitary MRI at Korea University Anam Hospital from March 2020 to September 2021. A total of 199 girls and 24 boys was enrolled in this study. Positive MRI findings were categorized as abnormal pituitary, nonpituitary incidental, and pathological. In addition, we investigated the incidence of MRI abnormalities and evaluated their associations with clinical and biochemical factors.Results: Positive brain MRI findings were observed in 84 patients (37.7%). Pituitary abnormalities were found in 54 patients (24.2%), with Rathke cleft cysts being the most common (16.1%). Incidental nonpituitary findings were observed in 29 patients (13.0%), while a pathological brain lesion (diagnosed as hypothalamic hamartoma) was observed in only 1 female patient (0.4%). No significant differences in sex or age were found in incidence of pituitary abnormalities or nonpituitary incidental findings. Compared with headache controls, significant associations were observed between abnormal pituitary findings on MRI and CPP (unadjusted odds ratio, 3.979; 95% confidence interval, 1.726–9.173).Conclusion: True pathological findings were rare, even though the prevalence of abnormalities on pituitary MRI in patients with CPP was relatively high. Considering its cost-effectiveness, MRI screenings should be carefully considered in patients with CPP.
- Open Access
- 1 January 2023
- Published by XMLink in Journal of Korean Medical Science
- Vol. 38 (13) , e96
Building of Pediatric COVID-19 Module Clinic: A Novel Operation Model in Response to COVID-19 Pandemic
Choe YJ, et al. J Korean Med Sci. 2023 Mar;38(13):e96. https://doi.org/10.3346/jkms.2023.38.e96
- 1 January 2023
- Published by XMLink in Journal of Korean Medical Science
- Vol. 38 (13) , e96
Open AccessBuilding of Pediatric COVID-19 Module Clinic: A Novel Operation Model in Response to COVID-19 Pandemic
Choe YJ, et al. J Korean Med Sci. 2023 Mar;38(13):e96. https://doi.org/10.3346/jkms.2023.38.e96
- Open Access
- 1 January 2021
- Published by XMLink in Pediatric Infection & Vaccine
- Vol. 28 (3) , 144-148
Decrease in Incidence of Febrile Seizure Following Social Distancing Measures: A National Cohort Study in South Korea
Park KH, et al. Pediatr Infect Vaccine. 2021 Dec;28(3):144-148. https://doi.org/10.14776/piv.2021.28.e20
- 1 January 2021
- Published by XMLink in Pediatric Infection & Vaccine
- Vol. 28 (3) , 144-148
Open AccessDecrease in Incidence of Febrile Seizure Following Social Distancing Measures: A National Cohort Study in South Korea
Park KH, et al. Pediatr Infect Vaccine. 2021 Dec;28(3):144-148. https://doi.org/10.14776/piv.2021.28.e20
- Open Access
- 1 January 2021
- Published by XMLink in Journal of Korean Medical Science
- Vol. 36 (46)
Trend of Antibiotic Use in Children with Acute Otitis Media in Korea
Park KH, et al. J Korean Med Sci. 2021 Nov;36(46):e317. https://doi.org/10.3346/jkms.2021.36.e317
- 1 January 2021
- Published by XMLink in Journal of Korean Medical Science
- Vol. 36 (46)
Open AccessTrend of Antibiotic Use in Children with Acute Otitis Media in Korea
Park KH, et al. J Korean Med Sci. 2021 Nov;36(46):e317. https://doi.org/10.3346/jkms.2021.36.e317